Cardiovascular disease (CVD) is a class of diseases that involve the heart or blood vessels. It is reported that body mass index (BMI) is risk factor for CVD[@b1]. To evaluate the association between BMI and CVD mortality, Chen *et al.* conducted a pooled analysis of 20 prospective cohorts in Asia, including data from 835,082 East Asians and 289,815 South Asians[@b1]. The results showed that a high BMI is a risk factor for mortality from overall CVD and for specific diseases, including coronary heart disease, ischaemic stroke, and haemorrhagic stroke in East Asians[@b1]. In the United States, all major Hispanic/Latino groups have a high prevalence of obesity. Kaplan *et al.* analyzed the CVD and BMI data from US Hispanic men (N = 6547) and women (N = 9797)[@b2]. They found that elevated BMI is common in Hispanic/Latino adults and is associated with a considerable excess of CVD risk factors[@b2].

Lamon-Fava *et al.* studied the distribution of BMI in men and women, and the association of BMI with known coronary heart disease (CHD) risk factors[@b3]. Their results indicate that increased BMI is associated with an adverse effect on all major CHD risk factors[@b3]. Loprinzi *et al.* examine the associations of underweight, overweight and obesity with kinds of CVD risk factors[@b4]. Their results showed that underweight adults had significantly lower levels of CRP; total cholesterol; total cholesterol to high-density lipoprotein cholesterol ratio; LDL cholesterol; and triglycerides compared to normal-weight individuals[@b4]. The overweight and obese adults had higher levels for each biomarker compared to normal-weight individuals[@b4].

Much effort has been put into identifying the genetic determinants of CVD. Genome-wide association studies (GWAS) have recently provided rapid insights into genetics of CVD and its risk factors[@b5][@b6][@b7][@b8][@b9][@b10][@b11]. However, these newly identified susceptibility loci exert very small risk effects and cannot fully explain the underlying genetic risk. A large proportion of heritability has yet to be explained. Recent pathway analyses of GWAS have been put in the investigation of human disease pathogenesis and yielded important new insights into genetic mechanisms of human complex diseases, such as Alzheimer's disease[@b12][@b13], and rheumatoid arthritis[@b14]. Until now, the specific mechanisms how BMI influences CVD risk are largely unknown. We think that BMI may influences CVD risk by shared genetic pathways. In order to confirm this view, we conducted a pathway analysis of BMI GWAS, which examined approximately 329,091 single nucleotide polymorphisms (SNPs) from 4763 samples.

Materials and Methods
=====================

Study Population
----------------

The study subjects were from members of the Northern Finnish Birth Cohort of 1966 (NFBC1966)[@b15]. Mothers expected to give birth in the two Northern provinces of Oulu and Lapland in 1966 were enrolled in the NFBC1966 (N = 12058 live births, Rantakallio 1969)[@b15]. Primary clinical data collection on parents and the child occurred prenatal and at birth. Data collection on the child continued at ages six months, one year, 14 years (no data from one year or 14 years are included in this paper), 31 years, with assessment of a wide range of trait measures[@b15]. Informed consent from all study subjects was obtained using protocols approved by the Ethical Committee of the Northern Ostrobothnia Hospital District. The methods were carried out in accordance with the approved guidelines. Participants provided fasting blood samples for evaluation of the metabolic measures[@b15]. 4763 samples were genotyped using Illumina Infinium 370cnvDuo array[@b15]. According to the exclusion criteria and quality control procedures, SNPs were included for following analysis if the call rate in the final sample was \>95%, if the P value from a test of Hardy-Weinberg Equilibrium (HWE) was \>0.0001, and if the Minor Allele Frequency (MAF) was \>1%[@b15]. In the end, 329,091 SNPs passed the quality controls and were selected for following analysis. For each SNP, the genotype was coded as 0, 1 or 2 copies of the minor allele. A regression analysis in PLINK was used to test the association between each SNP and BMI[@b15].

Gene-based testing for GWAS dataset
-----------------------------------

Here, we got the summary results from SNP-based test in the original study[@b15] and performed a gene-based testing for GWAS dataset. ProxyGeneLD was used to assign SNPs to specific genes[@b16]. ProxyGeneLD begins with the retrieval of linkage disequilibrium (LD) structures in the HapMap genotyping data[@b16]. If a group of markers is in high LD in HapMap (r^2^ \> 0.8), they are tied to a 'proxy cluster' and taken as a single signal[@b17]. Next, each marker in the BMI GWAS with statistically significant evidence of association is evaluated to see whether (a) it belongs to any proxy cluster and (b) whether the marker itself or any marker in the cluster is located in a genetic region[@b17]. If a marker or cluster overlaps a region extending across a gene, then it is assigned as showing possible association with that gene. Finally, a *P* value was given for each gene[@b16]. The *P* value was adjusted for the LD patterns in the human genome and gene length, but not multiple hypothesis testing correction. Genes with adjusted *P* \< 0.05 are considered to be significant. For more detailed algorithms, please refer to the original study and our previous publications[@b16].

Pathway-based testing for GWAS dataset
--------------------------------------

The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways in WebGestalt were used[@b18]. For a given pathway, the hypergeometric test was used to detect the overrepresentation of BMI-related genes among all of the genes in the pathway[@b18]. The false discovery rate (FDR) method was used to correct for multiple testing. Any pathway with an adjusted *P* \< 0.01 and at least five BMI genes was considered significant. In order to reduce the multiple-testing issue and to avoid testing overly narrow or broad pathways, we selected pathways that contained at least 20 and at most 300 genes for subsequent analysis.

Results
=======

Gene-based test for GWAS dataset
--------------------------------

We got 1008 significant BMI genes, which included 41 BMI genes with *P* \< 0.001. TFAP2B is the most significant gene, which is reported to be significantly associated with BMI by previous studies[@b19][@b20][@b21]. Meanwhile, we identified other new BMI susceptibility genes. These genes were significantly associated with BMI with *P* \< 0.001 ([Table 1](#t1){ref-type="table"}).

Pathway-based analysis of GWAS dataset
--------------------------------------

We identified 31 significant KEGG pathways with at least five BMI genes. Based on the classifications of the KEGG pathways, these 31 pathways can be mainly divided into environmental information processing (n = 6), cellular processes (n = 5), circulatory system cellular processes (n = 5), metabolism (n = 5), endocrine system (n = 2), genetic information processing (n = 2), immune system (n = 2), nervous system and diseases (n = 2), cardiovascular diseases (n = 1) ([Table 2](#t2){ref-type="table"}). The detailed genes in these significant pathways are described in [Supplementary Table 1](#S1){ref-type="supplementary-material"}.

Discussion
==========

In order to investigate how BMI influences CVD risk, we conducted a pathway analysis of BMI GWAS using 329,091 SNPs in 4763 Europeans. On the gene level, we identified 41 BMI genes with *P* \< 0.001. TFAP2B is the most significant signal. Previous studies supported significant association of TFAP2B with BMI[@b19][@b20][@b21]. Speliotes *et al.* analyzed 249,796 individuals and revealed 18 new loci associated with BMI. The TFAP2B rs987237 variant is significantly associated with BMI with *P* = 3.00E-20[@b19]. Berndt *et al.* identified 11 new loci for anthropometric traits. The TFAP2B rs987237 variant is significantly associated with BMI (*P* = 2.00E-11)[@b20]. Wen *et al.* conducted a meta-analysis of GWAS in East Asian-ancestry populations and reported TFAP2B rs9473924 variant is significantly associated with BMI (*P* = 4.00E-07)[@b21].

On the pathway level, we identified 31 significant KEGG pathways. Some of these pathways are identified to be associated with CVD. Here, we identified GnRH signaling pathway (hsa04912) to the second significant pathway. Sitras *et al.* conducted a gene expression profile analysis of CVD[@b22]. Gene set enrichment analysis showed significant association between GNRH signaling pathway and CVD[@b22].

Vascular smooth muscle contraction (hsa04270) is the 5^th^ significant signal in our research. The vascular smooth muscle cell is a highly specialized cell. The principal function of vascular smooth muscle cell is contraction. By contraction, vascular smooth muscle cells shorten and decrease the diameter of a blood vessel to regulate the blood flow and pressure. Evidence shows that abnormal contraction of vascular smooth muscle is a major cause of vasospasm of the coronary and cerebral arteries[@b23].

Here, we also highlighted the involvement of CVD related pathway in BMI. There are four CVD pathways in KEGG database, which include viral myocarditis (hsa05416), dilated cardiomyopathy (DCM) (hsa05414), hypertrophic cardiomyopathy (HCM) (hsa05410) and arrhythmogenic right ventricular cardiomyopathy (ARVC) (hsa05412). DCM is characterized by left ventricular dilation that is associated with systolic dysfunction[@b24]. In our research, we identified DCM to be significantly associated with AD with *P* = 3.30E-03.

There is also some literature evidence supporting the involvement of Gap junction, Wnt signaling, Calcium signaling and Chemokine signaling in CVD. More detailed information is described in [Table 3](#t3){ref-type="table"}.

Until now, there are kinds of software tools for pathway analysis of GWAS data[@b25]. Some tools including SNP ratio test[@b26], GenGen[@b27], GRASS[@b28], and PLINK set-test[@b29], accept raw genotype datasets as input data. Other tools including ProxyGeneLD[@b16], ALIGATOR[@b25], i-GSEA4GWAS[@b25], and GESBAP[@b25] accept the summary results to subsequent pathway analysis. Here, we selected ProxyGeneLD for gene-based test because we did not have access to raw CRC genotype data. This software adjusts for gene length and LD patterns in the human genome, which can reduce the sources of bias and increasing the reliability in pathway analysis. We selected the KEGG not the GO database for pathway analysis. It is reported that KEGG database is manually compiled based on biological evidence and does not have a hierarchical structure[@b30][@b31], whereas the GO database is based on computer predictions and human annotation. It has a hierarchical structure[@b30][@b31]. GO analysis typically assumes that each functional category is independent, and less than 1% of the GO annotations have been confirmed experimentally[@b30][@b31].

Despite these interesting results, we recognize some limitations in our study. Multiple testing corrections may not be sufficient to account for all biases in pathway analysis. The results from the BMI GWAS should be adjusted using a permutation test. However, the original SNP genotype data for each individual are not available to us now. When we get the SNP genotype data, we will further perform a pathway analysis using some available software such as SNP ratio test[@b26], GenGen[@b27], GRASS[@b28], and PLINK set-test[@b29]. These pathway analysis methods or software can be used to analyze the SNP genotype data, and can conduct a permutation test. Future replication studies using genotype data are required to replicate our findings.

Collectively, our study supports the potential role of the CVD risk pathways in BMI. BMI may influence CVD risk by the shared genetic pathways. We believe that our results advance our understanding of BMI mechanisms in CVD and will be very informative for future genetic studies in BMI and CVD.

Additional Information
======================

**How to cite this article**: Zhao, X. *et al.* Pathway analysis of body mass index genome-wide association study highlights risk pathways in cardiovascular disease. *Sci. Rep.* **5**, 13025; doi: 10.1038/srep13025 (2015).

Supplementary Material {#S1}
======================

###### Supplementary Table 1

This work was supported by funding from the National Nature Science Foundation of China (Grant No. 81300945).

**Author Contributions** X.Z., J.X., W.Y.S., G.M.S. and G.Y.L. conceived and initiated the project. G.Y.L. analyzed the data. X.Z., J.X., W.Y.S. and G.M.S. prepared the Tables. X.Z., J.X.G., M.L. and G.Y.L. wrote the manuscript. J.X.G. and M.L. revised the manuscript. All authors reviewed the manuscript, and contributed to the final manuscript.

###### The top 41 significant genes identified by gene-based analysis of BMI GWAS.

  Gene ID    Gene Symbol         Gene Position          Unadjusted P   Adjusted P   Gene ID
  --------- ------------- ---------------------------- -------------- ------------ ----------
  7021         TFAP2B       chr6:50894397--50923285       rs987237      7.37E-07    4.42E-06
  401036        ASB18      chr2:236768253--236837727     rs13386897     2.47E-06    1.97E-05
  64222         TOR3A      chr1:177317734--177331752     rs6425512      1.27E-05    3.82E-05
  4184          SMCP       chr1:151117421--151124147     rs3737861      2.10E-05    6.31E-05
  9917         FAM20B      chr1:177261696--177312321     rs6425512      1.27E-05    6.37E-05
  27            ABL2       chr1:177335084--177378834     rs6425512      1.27E-05    8.91E-05
  6646          SOAT1      chr1:177529639--177591076     rs6425512      1.27E-05    1.40E-04
  200186        CRTC2      chr1:152186775--152197667     rs11583896     1.55E-04    1.55E-04
  23360         FNBP4       chr11:47694644--47745569     rs12286721     6.58E-05    1.97E-04
  280636      C11orf31      chr11:57265297--57267459       rs9420       2.43E-04    2.43E-04
  64225         ATL2        chr2:38376627--38457919      rs6760123      8.28E-05    2.48E-04
  148327       CREB3L4     chr1:152207020--152213456     rs11583896     1.55E-04    3.10E-04
  285051       C2orf61      chr2:47209090--47235930      rs1880583      4.09E-05    3.27E-04
  64131         XYLT1       chr16:17103681--17472239      rs752482      6.97E-06    3.90E-04
  79841         AGBL2       chr11:47637718--47692878     rs12286721     6.58E-05    3.95E-04
  23279        NUP160       chr11:47756245--47826633     rs12286721     6.58E-05    3.95E-04
  10658        CUGBP1       chr11:47446520--47467152     rs12286721     6.58E-05    3.95E-04
  134353        LSM11      chr5:157103332--157116324     rs11738432     1.54E-04    4.61E-04
  9909         DENND4B     chr1:152168600--152185778     rs11583896     1.55E-04    4.65E-04
  4940          OAS3       chr12:111860631--111895438    rs10850109     1.17E-04    4.68E-04
  54956        PARP16       chr15:63337489--63366071      rs894494      1.22E-04    4.86E-04
  219541        MED19       chr11:57227762--57236249       rs9420       2.43E-04    4.86E-04
  10237        SLC35B1      chr17:45133688--45140281     rs2289600      2.59E-04    5.17E-04
  9717         SEC14L5       chr16:4948318--5009157      rs7191632      4.33E-05    5.63E-04
  148022       TICAM1        chr19:4766938--4782737      rs16992609     2.85E-04    5.71E-04
  56890         MDM1        chr12:66974612--67012428     rs10878810     9.97E-05    5.98E-04
  2841          GPR18       chr13:98704967--98708683     rs7325747      3.12E-04    6.23E-04
  26492         OR8G2      chr11:123600607--123601522    rs4936923      2.36E-04    7.09E-04
  10978         CLP1        chr11:57181205--57185913       rs9420       2.43E-04    7.30E-04
  51075        TXNDC14      chr11:57236617--57265020       rs9420       2.43E-04    7.30E-04
  54974         THG1L      chr5:157090900--157099350     rs11738432     1.54E-04    7.69E-04
  51368        TEX264       chr3:51680261--51713379      rs4974094      4.22E-04    8.44E-04
  130827       TMEM182     chr2:102744921--102800570     rs2540289      1.44E-04    8.64E-04
  84804         MFSD9      chr2:102700097--102719745     rs2540289      1.44E-04    8.64E-04
  5493           PPL         chr16:4872508--4927137      rs1049206      7.23E-05    8.68E-04
  57459        GATAD2B     chr1:152043826--152162075     rs11583896     1.55E-04    9.31E-04
  3682          ITGAE        chr17:3564667--3651286        rs2891       7.27E-05    9.45E-04
  25921        ZDHHC5       chr11:57192049--57225235       rs9420       2.43E-04    9.73E-04
  1500         CTNND1       chr11:57285809--57343228       rs9420       2.43E-04    9.73E-04
  3207         HOXA11       chr7:27187300--27191360      rs2189239      3.30E-04    9.90E-04
  253832       ZDHHC20      chr13:20848507--20931423     rs4770145      1.25E-04    9.97E-04

###### The significant KEGG pathways with *P* \< 0.01 by pathway analysis of BMI GWAS.

  Classifications                                        Pathway Name                  Pathway ID    C    O     E      R       rawP       adjP
  -------------------------------------- -------------------------------------------- ------------ ----- ---- ------ ------ ---------- ----------
  Endocrine system                                      Melanogenesis                   hsa04916    101   17   2.36   7.22   2.00E-10   1.38E-08
  Endocrine system                                  GnRH signaling pathway              hsa04912    101   13   2.36   5.52   6.89E-07   1.58E-05
  Circulatory system                                Gastric acid secretion              hsa04971    74    11   1.73   6.37   1.15E-06   1.98E-05
  Nervous system                                    Long-term potentiation              hsa04720    70    10   1.63   6.12   5.10E-06   7.04E-05
  Circulatory system                          Vascular smooth muscle contraction        hsa04270    116   12   2.71   4.43   1.81E-05   2.00E-04
  Cellular Processes                                    Oocyte meiosis                  hsa04114    112   11   2.61   4.21   6.49E-05   3.00E-04
  Cellular Processes                                     Gap junction                   hsa04540    90    10   2.1    4.76   4.84E-05   3.00E-04
  Circulatory system                                  Salivary secretion                hsa04970    89    10   2.08   4.82   4.39E-05   3.00E-04
  Environmental Information Processing              Wnt signaling pathway               hsa04310    150   13   3.5    3.72   5.43E-05   3.00E-04
  Environmental Information Processing            Calcium signaling pathway             hsa04020    177   14   4.13   3.39   7.73E-05   3.00E-04
  Genetic Information Processing                         Spliceosome                    hsa03040    127   12   2.96   4.05   4.49E-05   3.00E-04
  Immune system                                  Chemokine signaling pathway            hsa04062    189   15   4.41   3.4    4.18E-05   3.00E-04
  Metabolism                              Valine, leucine and isoleucine degradation    hsa00280    44    7    1.03   6.82   6.64E-05   3.00E-04
  Metabolism                                          Purine metabolism                 hsa00230    162   14   3.78   3.7    2.93E-05   3.00E-04
  Cellular Processes                                       Lysosome                     hsa04142    121   11   2.82   3.9    1.00E-04   4.00E-04
  Cellular Processes                                      Phagosome                     hsa04145    153   12   3.57   3.36   3.00E-04   1.10E-03
  Metabolism                                         Histidine metabolism               hsa00340    29    5    0.68   7.39   5.00E-04   1.70E-03
  Circulatory system                                 Pancreatic secretion               hsa04972    101   9    2.36   3.82   6.00E-04   2.00E-03
  Metabolism                                        Propanoate metabolism               hsa00640    32    5    0.75   6.7    8.00E-04   2.50E-03
  Cellular Processes                                     Endocytosis                    hsa04144    201   13   4.69   2.77   9.00E-04   2.70E-03
  Immune system                              Complement and coagulation cascades        hsa04610    69    7    1.61   4.35   1.10E-03   3.20E-03
  Cardiovascular diseases                           Dilated cardiomyopathy              hsa05414    90    8    2.1    3.81   1.20E-03   3.30E-03
  Circulatory system                                    Bile secretion                  hsa04976    71    7    1.66   4.23   1.30E-03   3.40E-03
  Environmental Information Processing            Hedgehog signaling pathway            hsa04340    56    6    1.31   4.59   1.90E-03   4.90E-03
  Environmental Information Processing      Phosphatidylinositol signaling system       hsa04070    78    7    1.82   3.85   2.30E-03   5.70E-03
  Genetic Information Processing                        RNA transport                   hsa03013    151   10   3.52   2.84   3.00E-03   7.10E-03
  Environmental Information Processing            Jak-STAT signaling pathway            hsa04630    155   10   3.62   2.77   3.60E-03   7.80E-03
  Infectious diseases: Parasitic                          Amoebiasis                    hsa05146    106   8    2.47   3.24   3.40E-03   7.80E-03
  Metabolism                                          Lysine degradation                hsa00310    44    5    1.03   4.87   3.50E-03   7.80E-03
  Environmental Information Processing      Cytokine-cytokine receptor interaction      hsa04060    265   14   6.18   2.26   4.10E-03   8.30E-03
  Neurodegenerative diseases                         Huntington's disease               hsa05016    183   11   4.27   2.58   4.00E-03   8.30E-03

C, the number of reference genes in the category; O, the number of genes in the gene set and also in the category; E, expected number in the category; R, the ratio of enrichment, rawP, the p value from hypergeometric test; adjP, the p value adjusted by the multiple test adjustment.

###### Literature evidence supporting pathways associated with CVD.

  Pathway                                                                                                                       Supporting evidence                                                                                                           Ref
  --------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------
  Gap junction                                Connexins, the protein molecules forming gap junction channels, are reduced in number or redistributed from intercalated disks to lateral cell borders in a variety of cardiac diseases                        [@b32]
  Gap junction                                                       Alterations of gap junction organization and connexin expression are now well established as a consistent feature of human heart disease                                                [@b33]
  Wnt signaling                     Emerging evidence indicates that Wnt signaling regulates crucial aspects of cardiovascular biology (including cardiac morphogenesis, and the self-renewal and differentiation of cardiac progenitor cells).              [@b34]
  Wnt signaling                                                                        Wnt signaling pathways play a key role in cardiac development, angiogenesis, and cardiac hypertrophy                                                                  [@b35]
  Calcium signaling      Ca(2+)-related miRNAs have been found to be significant pathophysiological contributors in conditions like myocardial ischemic injury, cardiac hypertrophy, heart failure, ventricular arrhythmogenesis, and atrial fibrillation.   [@b36]
  Chemokine signaling                                                            There is growing evidence to suggest that chemokines play an important pathogenic role in cardiovascular diseases                                                           [@b37]
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